NCT01131637

Brief Summary

The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
331

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Apr 2010

Geographic Reach
1 country

43 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 25, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 27, 2010

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2012

Completed
Last Updated

December 21, 2017

Status Verified

July 1, 2012

Enrollment Period

2.2 years

First QC Date

May 25, 2010

Last Update Submit

December 19, 2017

Conditions

Keywords

chronic heart failurerhNRG-1mortality

Outcome Measures

Primary Outcomes (1)

  • all cause mortality

    one year

Study Arms (2)

rhNRG-1

EXPERIMENTAL

recombinant human neuregulin-1

Drug: rhNRG-1

placebo

PLACEBO COMPARATOR

placebo

Drug: placebo

Interventions

day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection

rhNRG-1

day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection

placebo

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18 and 80, both sex.
  • Left ventricular ejection fraction (LVEF)≤40% (ECHO).
  • NYNA functional class III\~Ⅳ.
  • Clinical symptom is steadily in the latest 1 week (no fluid retension, no weight gain).
  • Capable of signing the informed consent form.

You may not qualify if:

  • Patients with acute pulmonary edema or acute hemodynamic disorder.
  • Patients with right heart failure caused by pulmonary disease.
  • Patients diagnosed with pericardial effusion or pleural effusion.
  • Patients with myocardial infarction during the preceding 3 months.
  • Patients with constrictive pericarditis, significant valvular pathological change or congenital heart diseases, severe pulmonary artery hypertension.
  • Unstable angina pectoris.
  • Cardiac surgery or cerebrovascular accident within recent six months.
  • Preparing for heart transplantation.
  • Serious ventricular arrhythmia (multi-morphological premature ventricular contraction, frequent paroxysmal ventricular tachycardia).
  • Serious hepatic or renal dysfunction caused by organic pathological changes (Cr\>3.0mg/dl, AST or ALT 10 times above the normal upper limit).
  • Serum potassium \<3.2 mmol/L or \>5.5 mmol/L.
  • Systolic blood pressure \<90mmHg or \>160mmHg.
  • Pregnant or plan to pregnant.
  • Patients who participated in any clinical trial in the recent three months.
  • Subject with a life expectancy less than 3 months as assessed by the investigator.
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (43)

General Hospital of Chinese People's Liberation Army

Beijing, Beijing Municipality, China

Location

The First Hospital affiliated to Lanzhou University

Lanzhou, Gansu, China

Location

Haikou Municipal Peoples Hospital

Haikou, Hainan, China

Location

Bethune International Peace Hospital

Shijiazhuang, Hebei, China

Location

Teda International Cardiovascular Hospital

Tianjin, Hebei, China

Location

Daqing Oilfield General Hospital

Daqing, Heilongjiang, China

Location

The First Hospital of Harbin Medical University

Haerbin, Heilongjiang, China

Location

The First hospital affiliated to Zhengzhou University

Zhengzhou, Henan, China

Location

Zhongnan Hospital of Wuhan University

Wuchang, Hubei, China

Location

Tongji Hospital Affiliated to Huazhong University of Science and Technology

Wuhan, Hubei, China

Location

Hunan Provincial People's Hospital

Changsha, Hunan, China

Location

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China

Location

Jiangsu Jiangyin People's Hospital

Jiangyin, Jiangsu, China

Location

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China

Location

Zhongda Hospital, Southeast University

Nanjing, Jiangsu, China

Location

The Second Hospital affiliated to Suzhou University

Suzhou, Jiangsu, China

Location

The Affiliated Hospital of Xuzhou Medical School

Xuzhou, Jiangsu, China

Location

North Jiangsu People's Hospital

Yangzhou, Jiangsu, China

Location

The Affiliate Hospital of Jiangsu University

Zhenjiang, Jiangsu, China

Location

The Second Hospital affiliated to Jilin University

Changchun, Jilin, China

Location

The First Hospital affiliated to Dalian Medical University

Dalian, Liaoning, China

Location

The first affiliated hospital of Liaoning medical college

Jinzhou, Liaoning, China

Location

Liaoning Provincial People's Hospital

Shenyang, Liaoning, China

Location

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China

Location

The First Hospital of China Medical Hospital

Shenyang, Liaoning, China

Location

Qilu Hospital of Shandong University

Jinan, Shandong, China

Location

The Second Hospital of Shandong University

Jinan, Shandong, China

Location

Shanxi Provincial People's Hospital

Xi’an, Shanxi, China

Location

The second hospital of Xi'an jiaotong university

Xi’an, Shanxi, China

Location

Huaxi Hospital of Sichuan University

Chengdu, Sichuan, China

Location

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Location

The Xinqiao Hospital of Third Military Medical University

Chongqin, Sichuan, China

Location

Kunming General Hospital of Chengdu Military Region

Kunming, Yunnan, China

Location

The Second hospital affiliated to Kunming Medical and Pharmaceutical College

Kunming, Yunnan, China

Location

Sir Run Run Shaw Hospital affiliated to School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Location

The First Hospital affiliated to School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

Location

Beijing Anzhen Hospital, Affiliate of Capital University of Medical Sciences

Beijing, China

Location

Beijing Chao Yang Hospital, Affiliate of Capital University of Medical Sciences

Beijing, China

Location

Cardiovascular Institute and Fuwai Hospital

Beijing, China

Location

Huashan Hospital affiliated to Fudan University

Shanghai, China

Location

Renji Hospital, Medical School of Shanghai Jiaotong University

Shanghai, China

Location

The first people's hospitial of Shanghai

Shanghai, China

Location

The Sixth People's Hospital, Shanghai Jiaotong University

Shanghai, China

Location

Study Officials

  • Runlin Gao, MD,Ph.D

    Cardiovascular Institute and Fuwai Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2010

First Posted

May 27, 2010

Study Start

April 1, 2010

Primary Completion

June 1, 2012

Study Completion

August 1, 2012

Last Updated

December 21, 2017

Record last verified: 2012-07

Locations